https://www.pharmaradar360.com/article/566322c8b5c66c6dPharmaRadar360en2026-04-03T12:26:00.000ZOffering scientists cash to spot errors in published papers doesn’t workhttps://www.pharmaradar360.com/article/627f15bbcb0fdfc1PharmaRadar360en2026-04-03T10:00:00.000ZTrastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancerhttps://www.pharmaradar360.com/article/33b3bcb4e1140024PharmaRadar360en2026-04-03T10:00:00.000ZThe Fetal-to-Adult Hemoglobin Switch - Mechanism and Therapyhttps://www.pharmaradar360.com/article/9813c00f3d9cfc61PharmaRadar360en2026-04-03T10:00:00.000ZDigital Twin-Guided Ablation for Ventricular Tachycardiahttps://www.pharmaradar360.com/article/5d9e823dc8e3fe97PharmaRadar360en2026-04-03T10:00:00.000ZMore Options for Gene Editing in Hemoglobinopathieshttps://www.pharmaradar360.com/article/72aa42f03ef82756PharmaRadar360en2026-04-03T10:00:00.000ZMinocycline-Induced Hyperpigmentationhttps://www.pharmaradar360.com/article/0df37fb116a544faPharmaRadar360en2026-04-03T10:00:00.000ZClinical Examination of the Lumbar Spinehttps://www.pharmaradar360.com/article/e7cf70146008dacaPharmaRadar360en2026-04-03T10:00:00.000ZGLP-1 Receptor Agonistshttps://www.pharmaradar360.com/article/88f41ecbec272468PharmaRadar360en2026-04-03T10:00:00.000ZErratum: Tissue-Free Circulating Tumor DNA Assay and Patient Outcome in a Phase III Trial of FOLFOX-Based Adjuvant Chemotherapy (Alliance N0147)https://www.pharmaradar360.com/article/b8072a374bbedbc9PharmaRadar360en2026-04-03T03:00:00.000Z[SHINSA]English translation of review report: Peripheral Rotablator PRO and Visual-ICE Cryoablation System (Partial Change Approval)https://www.pharmaradar360.com/article/bc0a96684d6a00a5PharmaRadar360en2026-04-03T01:00:00.000ZMenicon Renames Its Sales Subsidiaries in Malaysia and Indonesia – Promoting Brand Integration and Business Expansion in Southeast Asia –https://www.pharmaradar360.com/article/f0a809b2df1cd379PharmaRadar360en2026-04-03T00:00:00.000ZBristol Myers Squibb to Report Results for First Quarter 2026 on April 30, 2026https://www.pharmaradar360.com/article/8b5819ac0ffc3fb5PharmaRadar360en2026-04-03T00:00:00.000ZProfiling KRAS mutations in whole blood by error-corrected maximum depth sequencinghttps://www.pharmaradar360.com/article/721ba76c6198b4a6PharmaRadar360en2026-04-03T00:00:00.000ZBazar el Regalo raises €13,644 for personalised medicine and paediatric cancer researchhttps://www.pharmaradar360.com/article/c5fb628b9091cf79PharmaRadar360en2026-04-03T00:00:00.000ZMedicines Australia firmly oppose US tariffs on pharmaceuticalshttps://www.pharmaradar360.com/article/668db4657b1aaf6bPharmaRadar360en2026-04-03T00:00:00.000ZIpsen announces that Beech Tree has obtained an exemption from the obligation to submit a public tender offerhttps://www.pharmaradar360.com/article/fdac9ccf095c0fe2PharmaRadar360en2026-04-02T22:35:27.000ZFDA alerts consumers and pet owners of Silver Star Brand’s voluntary recall of homeopathic drug productshttps://www.pharmaradar360.com/article/581b10efad3968a5PharmaRadar360en2026-04-02T22:34:48.000ZFDA alerts consumers of Sprayology’s voluntary nationwide recall of homeopathic water-based medicines due to microbial contaminationhttps://www.pharmaradar360.com/article/94935caa34086a09PharmaRadar360en2026-04-02T22:34:00.000ZFDA alerts patients and health care professionals that some EpiPen auto-injectors may not readily slide out of carrier tubehttps://www.pharmaradar360.com/article/41e05c51cb7a0d6cPharmaRadar360en2026-04-02T22:31:40.000ZFDA alerts health care professionals and patients not to use drug products intended to be sterile from Promise Pharmacyhttps://www.pharmaradar360.com/article/7f4a721d1ae72d9bPharmaRadar360en2026-04-02T22:30:54.000ZFDA alerts consumers not to use two e-liquids sold by HelloCig Electronic Technologyhttps://www.pharmaradar360.com/article/2b9faf646cddf03cPharmaRadar360en2026-04-02T22:29:58.000ZFDA warns compounders not to use glutathione from Letco Medical to compound sterile drugshttps://www.pharmaradar360.com/article/de61b5525a07ba78PharmaRadar360en2026-04-02T22:27:03.000ZFDA alerts patients of McDaniel Life-Line’s voluntary recall of Indian Herbhttps://www.pharmaradar360.com/article/cab967bcd2e19b2fPharmaRadar360en2026-04-02T20:54:05.000ZFDA alerts patients and healthcare professionals to Infusion Options’ voluntary recall due to quality issueshttps://www.pharmaradar360.com/article/541e9a29c8aed0ecPharmaRadar360en2026-04-02T20:53:15.000ZFDA alerts consumers not to use Kratom NC’s productshttps://www.pharmaradar360.com/article/f47f26eee1a65c57PharmaRadar360en2026-04-02T20:51:18.000ZFDA advises patients not to use Herbal Doctor Remedies’ medicineshttps://www.pharmaradar360.com/article/6edb817a4223a798PharmaRadar360en2026-04-02T19:49:30.000ZJuly - September 2023 Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)https://www.pharmaradar360.com/article/27255279d1198fa8PharmaRadar360en2026-04-02T19:38:50.000ZJanuary - March 2023 Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)https://www.pharmaradar360.com/article/79b712920e674321PharmaRadar360en2026-04-02T19:38:38.000ZOctober - December 2023 Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)https://www.pharmaradar360.com/article/b769550b5ab67d46PharmaRadar360en2026-04-02T19:38:35.000ZApril - June 2025 Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)https://www.pharmaradar360.com/article/70e17346711d3047PharmaRadar360en2026-04-02T17:58:10.000ZFDA advises consumers not to use Rompe Pecho cough syruphttps://www.pharmaradar360.com/article/ac9998bb6b3644fdPharmaRadar360en2026-04-02T17:57:12.000ZFDA alerts patients and health care professionals of Amneal and Impax Laboratories epinephrine auto-injector device malfunctionshttps://www.pharmaradar360.com/article/ba6e96e06fa80c63PharmaRadar360en2026-04-02T17:56:02.000ZFDA updates on hand sanitizers consumers should not usehttps://www.pharmaradar360.com/article/214d18112c1cdc41PharmaRadar360en2026-04-02T17:29:14.000ZUK and US deepen regulatory cooperation on medical devices, building on wider pharmaceutical partnershiphttps://www.pharmaradar360.com/article/3c3e82bc6cb61f4aPharmaRadar360en2026-04-02T16:51:32.000ZWhat’s New for Biologicshttps://www.pharmaradar360.com/article/7204432004aeca39PharmaRadar360en2026-04-02T16:08:00.000ZNHS patients and British businesses to benefit from historic changes to medicines access following pharmaceutical partnership with USAhttps://www.pharmaradar360.com/article/9e969e73c1339af9PharmaRadar360en2026-04-02T16:00:00.000ZLa FDA aprueba Foundayo™ (orforglipron) de Lilly, la única pastilla GLP-1 para la pérdida de peso que puede tomarse a cualquier hora del día sin restricciones de comida o aguahttps://www.pharmaradar360.com/article/809f781b03546ba7PharmaRadar360en2026-04-02T15:51:06.000ZFDA Grand Rounds – Adeno-associated Virus-mediated Gene Therapy: Advances, Immune Challenges, and Research Innovations - 02/19/2026https://www.pharmaradar360.com/article/91dc5698d61ebae1PharmaRadar360en2026-04-02T14:51:00.000ZDecision: Advertising investigations: March 2026https://www.pharmaradar360.com/article/012ae8a4ede7b4e6PharmaRadar360en2026-04-02T13:35:13.000ZCinglan 30 mg-Filmtablettenhttps://www.pharmaradar360.com/article/4387a8639a1018acPharmaRadar360en2026-04-02T12:30:00.000ZAbeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in New Yorkhttps://www.pharmaradar360.com/article/4ee85ecdd20d96d3PharmaRadar360en2026-04-02T12:00:00.000ZEmergent BioSolutions Participates in Upcoming International Preparedness Conferenceshttps://www.pharmaradar360.com/article/768bba8cdfa09d51PharmaRadar360en2026-04-02T10:00:00.000ZNew subcutaneous nodules and joint pain in a patient with pancreatic cancerhttps://www.pharmaradar360.com/article/b75ef380d79a6b85PharmaRadar360en2026-04-02T10:00:00.000ZAnti-infective vaccination strategies in patients with haematological malignancies or solid tumours: updated guideline of the Infectious Diseases Working Party of the German Society for Hematology and Medical Oncologyhttps://www.pharmaradar360.com/article/72b64b8b1118658ePharmaRadar360en2026-04-02T10:00:00.000ZPrinciples of cytoreductive surgery for primary and metastatic peritoneal malignancies-the PSOGI-ESGO-ISSPP Lyon consensushttps://www.pharmaradar360.com/article/7e67df2c6d058083PharmaRadar360en2026-04-02T10:00:00.000ZALND after neoadjuvant chemotherapy: a call for caution - Authors' replyhttps://www.pharmaradar360.com/article/f89bb53b24d9ed1dPharmaRadar360en2026-04-02T10:00:00.000ZALND after neoadjuvant chemotherapy: a call for cautionhttps://www.pharmaradar360.com/article/bda6431d3f0a3b66PharmaRadar360en2026-04-02T10:00:00.000ZInterpretation of constitutional cancer predisposition gene variants in 14 765 individuals in the 100 000 Genomes Project cancer arm: a retrospective cohort analysishttps://www.pharmaradar360.com/article/83796b97800eac90PharmaRadar360en2026-04-02T10:00:00.000ZIfinatamab deruxtecan, a B7-H3-directed antibody-drug conjugate, in patients with advanced solid tumours (IDeate-PanTumor01): dose-escalation results from a phase 1/2 trialhttps://www.pharmaradar360.com/article/63a4e32e5acf4271PharmaRadar360en2026-04-02T10:00:00.000Z[ 177 Lu]Lu-PSMA-617 in combination with pembrolizumab for treatment of metastatic castration resistant prostate cancer (PRINCE): a single-arm, phase 1b/2 studyhttps://www.pharmaradar360.com/article/f625beb05c840107PharmaRadar360en2026-04-02T10:00:00.000Z[ 177 Lu]-PSMA-617-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 studyhttps://www.pharmaradar360.com/article/01199b4edac9d6efPharmaRadar360en2026-04-02T10:00:00.000ZChemoradiotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancerhttps://www.pharmaradar360.com/article/ffbd9ec572871548PharmaRadar360en2026-04-02T10:00:00.000ZReply to: "Chemoradiotherapy in Pancreatic Cancer: Toward Precision Oncology," "Key Methodological Considerations in the Interpretation of the CONKO-007 Trial," and "Chemoradiotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer"https://www.pharmaradar360.com/article/7ef4d6e4bee2a79fPharmaRadar360en2026-04-02T10:00:00.000ZKey Methodological Considerations in the Interpretation of the CONKO-007 Trialhttps://www.pharmaradar360.com/article/581b8a52f3aee7c1PharmaRadar360en2026-04-02T10:00:00.000ZChemoradiotherapy in Pancreatic Cancer: Toward Precision Oncologyhttps://www.pharmaradar360.com/article/510389248faad67cPharmaRadar360en2026-04-02T10:00:00.000ZGonadal Function and Fertility after Hodgkin Lymphoma Treatment with Nivolumab-AVD in the Phase II GHSG NIVAHL Trialhttps://www.pharmaradar360.com/article/1b009c8256c4a364PharmaRadar360en2026-04-02T10:00:00.000ZBreaking new ground with antibody-drug conjugates in myelomahttps://www.pharmaradar360.com/article/fdd23a77c0eda5b2PharmaRadar360en2026-04-02T10:00:00.000ZAccess to CAR T-cell therapy across diverse global marketshttps://www.pharmaradar360.com/article/619f30f00d008d8bPharmaRadar360en2026-04-02T10:00:00.000ZFan X, Xi Q. Flow cytometry-based evaluation of TRBC1/TRBC2 facilitates identification of indolent T-lymphoblastic proliferations. Blood. 2026;147(6):702https://www.pharmaradar360.com/article/f64306a5c5d5c405PharmaRadar360en2026-04-02T10:00:00.000ZArora J, Ayyappan S, Yin C, et al. T-cell help in the tumor microenvironment enhances rituximab-mediated NK-cell ADCC. Blood. 2024;143(18):1816-1824https://www.pharmaradar360.com/article/41d6eeb0b5a0f6e4PharmaRadar360en2026-04-02T10:00:00.000ZMetamizole-induced agranulocytosis resulting in ecthyma gangrenosum after an AI chatbot queryhttps://www.pharmaradar360.com/article/6804dd1e2b2bb706PharmaRadar360en2026-04-02T09:11:50.000ZSevabertinib approved to treat adults with HER2-positive lung cancer that has spread or cannot be removed by surgery